These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7915124)

  • 1. A phase II study of effect of addition of trichosanthin to zidovudine in patients with HIV disease and failing antiretroviral agents.
    Byers VS; Levin AS; Malvino A; Waites L; Robins RA; Baldwin RW
    AIDS Res Hum Retroviruses; 1994 Apr; 10(4):413-20. PubMed ID: 7915124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
    Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
    Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Once-daily administration of didanosine in combination with anti-retroviral zidovudine in previously untreated patients].
    Reynes J; Montes B; Delmas B; Vendrell JP; Janbon F; Segondy M
    Pathol Biol (Paris); 1997 May; 45(5):441-4. PubMed ID: 9296101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo].
    Dokekias AE; Galiba FO; Bokilo AD; Ntsimba P; Nsitou MB; Malanda F; Basseila GB
    Bull Soc Pathol Exot; 2008 Apr; 101(2):109-12. PubMed ID: 18543703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients.
    Easterbrook PJ; Emami J; Gazzard B
    AIDS; 1993 Oct; 7(10):959-67. PubMed ID: 7903542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection.
    Yarchoan R; Lietzau JA; Nguyen BY; Brawley OW; Pluda JM; Saville MW; Wyvill KM; Steinberg SM; Agbaria R; Mitsuya H
    J Infect Dis; 1994 Jan; 169(1):9-17. PubMed ID: 7903976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy.
    Yarchoan R; Venzon DJ; Pluda JM; Lietzau J; Wyvill KM; Tsiatis AA; Steinberg SM; Broder S
    Ann Intern Med; 1991 Aug; 115(3):184-9. PubMed ID: 1676252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
    Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
    AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of combining zidovudine plus didanosine in patients with and without previous exposure to zidovudine].
    Gómez-Cano M; Soriano V; García-Lerma G; González-Lahoz J
    An Med Interna; 1998 Mar; 15(3):145-7. PubMed ID: 9567422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of trichosanthin treatment of HIV disease.
    Byers VS; Levin AS; Waites LA; Starrett BA; Mayer RA; Clegg JA; Price MR; Robins RA; Delaney M; Baldwin RW
    AIDS; 1990 Dec; 4(12):1189-96. PubMed ID: 2128454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection.
    Simonelli C; Zanussi S; Sandri S; Comar M; Lucenti A; Talamini R; Bortolin MT; Giacca M; De Paoli P; Tirelli U
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Jan; 20(1):20-7. PubMed ID: 9928725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group.
    Gatell J; Lange J; Gartland M
    Antivir Ther; 1999; 4(2):79-86. PubMed ID: 10682152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
    Losso MH; Belloso WH; Emery S; Benetucci JA; Cahn PE; Lasala MC; Lopardo G; Salomon H; Saracco M; Nelson E; Law MG; Davey RT; Allende MC; Lane HC
    J Infect Dis; 2000 May; 181(5):1614-21. PubMed ID: 10823761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
    Lancet; 1999 Jun; 353(9169):2014-25. PubMed ID: 10376616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
    Duvivier C; Myrto A; Marcelin AG; Ghosn J; Ait-Mohand H; Schneider L; Agher R; Bricaire F; Costagliola D; Calvez V; Peytavin G; Katlama C
    Antivir Ther; 2003 Dec; 8(6):603-9. PubMed ID: 14760894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
    Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
    Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.